Soy, rice and peas still dominate the plant-based protein market, but chickpeas could soon give them all a serious run for their money, predicts Israeli start-up CHiCK.P, which is seeking a strategic partner to commercialize its patent-pending process for producing highly functional ‘flavorless’ chickpea proteins.
The brainchild of Ram Reifen MD, MSc Nutrition, MBA – professor of human nutrition at the Hebrew University of Jerusalem and director of its center for nutrigenomics and functional foods - CHiCK.P has secured initial funding from Agrinnovation, an agricultural venture capital fund that’s part of the university’s Yissum technology transfer arm.
Speaking to FoodNavigator-USA during a press trip to Israel organized by the Israel Export Institute, Professor Reifen said CHiCK.P had developed concentrates with 60-90% protein and isolates with 90%+ protein, and was now looking for a partner to whom it could license the technology to produce the proteins on a commercial scale (currently production is at pilot scale).
Therapix Biosciences Ltd. (NASDAQ, TASE: TRPX), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based drugs, today announced that it has signed a sublicense agreement for Yissum Research Development Company of the Hebrew University Ltd.'s nasal drug delivery technology.
Under the terms of the agreement, Yissum will grant Therapix an exclusive, worldwide, sub-licensable, royalty-bearing license to its technology for the nasal delivery of cannabinoids.
The technology, developed by Professor Elka Touitou from the Institute of Drug Research at the Hebrew University of Jerusalem, facilitates administration and effective nasal absorption of tetrahydrocannabinol, or THC, the active pharmaceutical ingredient in the drugs developed by Therapix.
You’re a first-time visitor to Jerusalem, what sites are likely to arouse the strongest feelings? Naturally one would be the Western Wall, but how about the Daniel Auster Garden next to city hall?
Prof. Noam Shoval, Yonatan Schvimer and Prof. Maya Tamir – all of the Hebrew University – set out to find out what were the peak tourism experiences in Jerusalem using a combination of objective and subjective measures.
Intel agreed on Monday to pay $15.3 billion for Mobileye, an Israeli technology company that specializes in making sensors and cameras for autonomous cars, as the global microchip giant tries to expand its reach in the fast-growing sector.
The deal follows a growing partnership between Intel and Mobileye. In January, the companies announced plans to have up to 40 autonomous cars on American and European roads by the end of this year as part of trials with BMW, the German automaker.
An Israeli initiative that empowers parents to take the reins in educating their preschoolers is now about to expand to China and South Korea.
Aiming to equip parents to become their child’s first teacher, the Home Instruction for Parents and Preschool Youngsters (HIPPY) program – owned by the Yissum Research Development Company of the Hebrew University of Jerusalem will soon be coming to two Asian markets.
From research to agricultural and technical innovation and liberal government policies, Israel is a central hub for advancing medical cannabis.
MercuRemoval, developer of gas treatment solutions, recently announced successful results of a trial in which its technology demonstrated dramatically high efficiency in removing mercury from flue gas emission, with mercury absorption and removal rate reaching 98%. The trials are conducted in collaboration with Israel Electric Corporation (IEC). The technology was developed by Professor Yoel Sasson and Dr. Zach Barnea, both from the Casali Institute of Applied Chemistry of the Hebrew University of Jerusalem and was licensed under an exclusive worldwide agreement from Yissum, the technology transfer company of the Hebrew University.
The sleepy capital is becoming a hi-tech hub to be reckoned with.
TyrNovo is developing NT219, a small molecule originally developed by Dr. Hadas Reuveni and Prof. Alexander Levitzki at the Hebrew University, and exclusively licensed from Yissum, the Hebrew University Research Development Company. TyrNovo demonstrated the potential of NT219 to overcome resistance to multiple anti-cancer drugs, by using the Patient-Derived Xenograft (PDX) models, in collaboration with Prof. Izhak Haviv from the Bar-Ilan University and Prof. M. Stemmer from Clalit HMO.
No less than 50 Israeli start ups currently develop Cannabis-related technologies, and the Hebrew University's new startup CannabiTech is here to make a change.
Nutraceutical pain reliever makes use of marijuana’s CBD compound, doesn’t make you high.
Sales based on Israeli startup Lyotropic Delivery Systems (LDS) Biotech‘s nanotechnology have started in the US. The commercial launch of its cannabis-derived compound, which aims to relieve inflammation and pain, was announced earlier this month by LDS and US based company Ananda Scientific at a marijuana business conference held in Las Vegas.
The potential of the students' project was first identified at a science fair by Tamir Huberman a business development specialist for the university's for-profit company, Yissum, which aims to turn the best ideas originated at the university into businesses. He says "as a rule of thumb" about $500,000 is needed to help fund the wider trials and get this technology into development . It is hoped it will be available within two years.
Still controversial in the US, Israel is leading the way to develop the next generation of Medical Cannabis.
Just last month, Yissum (the technology transfer company of the Hebrew University) announced that Agrinnovation, its investment fund focused on agricultural innovation, has entered into an investment agreement with MC company Cannabi-Tech. In a company announcement, Agrinnovation General Manager Dr. Ido Schechter said that, “As the MC industry expands worldwide, there will be a significant rise in regulatory oversight, increased quality assurance and quality control testing, while growing market demand will need to be fulfilled by mass production.”
Atox Bio, a clinical stage company developing novel immunemodulators for critically ill patients with severe infections, today announced the independent Data Monitoring Committee (DMC) completed its pre-planned safety review of the first 50 patients enrolled in the company's ACCUTE trial and recommended that the study, evaluating novel candidate AB103 for the treatment of Necrotizing Soft Tissue Infections ("Flesh Eating Bacteria"), continue without modification.
Drug now being tested causes HIV-infected cells to self-destruct without harming the rest of the body
Agrinnovation puts money into Cannabi-Tech, developer of an analysis device for medical marijuana flowers
Granalix BioTechnologies today announced the commercial launch of GranaGard™ a food supplement based on pomegranate oil that was shown to prevent neurodegeneration diseases in mouse models.
Granalix BioTechnologies focuses on developing science-based novel formulations of natural antioxidants that can be used for the prevention and treatment of neurodegenerative conditions. The Company was established in 2014 by Prof. Ruth Gabizon from the Department of Neurology at Hadassah Medical Center, Jerusalem, Israel and Prof.Shlomo Magdassi at the Casali Center for Applied Chemistry, the Institute of Chemistry and the Center for Nanoscience and Nanotechnology at the Hebrew University of Jerusalem, as a spinoff of Yissum Research Development Company of the Hebrew University of Jerusalem, the technology-transfer company of the Hebrew University, and Hadasit, the Technology Transfer Company of Hadassah Medical Organization.
BriefCam was added to the toolbox of Hartford's Real-Time Crime and Data Intelligence Center about three months ago, after members of the center's staff first saw it in action at ESPN, which sometimes aids police with enhancing video files.
Agrinnovation, the agri-tech investment fund of Hebrew University of Jerusalem technology commercialization company Yissum, has announced an investment in a medical cannabis venture. Cannabi-Tech is based on research by cofounder and chief scientific officer Prof. Oded Shoseyov, whose technologies are also the basis for other startups, including Collplant and Fulcrum.
Inventions using sound and touch soon to be commercialized from Israeli professor’s lab will give unprecedented abilities to people with visual limitations.